Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Labs, Stanford Pen Cardiovascular-Research Alliance

NEW YORK, Oct. 2 (GenomeWeb News) - Agilent Technologies and Stanford University will use Agilent's gene-expression technologies and computational expertise to analyze cardiovascular tissue samples from human patients, the groups said today.


Stanford's DonaldW.ReynoldsCardiovascularClinicalResearchCenterand Agilent Labs hope to use the technologies to identify, characterize, and validate diagnostic and drug targets that may help prevent, diagnose, and treat heart disease, according to a statement.


Financial terms of the agreement were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.